PHARMAC performance 2016/17 Q1
Performance data to 30 September 2016/17
Output Class 1: Decision-making
Measure: All funding decisions are supported by evidence and made using PHARMAC’s decision-making approach.
Status: On track. All funding decisions supported by evidence and made using PHARMAC’s decision-making approach.
Measure: Decisions on more than 90% of line items (excluding bids held open while awaiting Medsafe registration) will be made within six months of the tender closing.
Status: On track. The tender is due to be released in early November; the closing date is late December.
Measure: Cumulative five year value to Vote Health at 30 June 2017 exceeds cumulative five year value of additional baseline contribution to PHARMAC’s operation.
Status: On track. Five year cumulative value of all decisions since 2013/14 is $214.83 million across both hospital medicines and devices, well in excess of the five-year value of PHARMAC’s baseline funding.
Output Class 2: Influencing medicines use
Measure: At least half of all DHBs or agents will engage with PHARMAC on implementing hospital medical device national contracts.
All relevant DHB hospital services will engage with PHARMAC to support hospital medicine changes.
Status: On Track. All DHBs engaged with PHARMAC either face to face or via teleconference for hospital medical devices around the market share for wound care changes.
20 representatives from DHB hospital infusion services attended a workshop on nivolumab (treatment for melanoma). All DHBs received a targeted consultation on a proposal for Roche products which provided estimated impacts on DHB services.
Measure: Surveys of attendees show at least 90% of surveyed attendees rate their satisfaction with the Seminars at least four out of five.
Status: On Track. 95% of attendees at the 4 seminars between 30 June and 30 September 2016 rate their satisfaction with the seminars at least 4 out of 5.
Measure: Community-based delivery of HRPHOW programme occurs with at least 3 MoA partners.
Status: On track. The two one-day HRPHOW MoA partner pilots have been completed. An independent evaluation of the two pilots is now underway. 3 MoA partner HRPHOW wānanga are planned for 2016/17.
Measure: Respond to low medicine stock reports, communicate effectively and take action as necessary to ensure patient needs for medicines are met.
Status: On track. All stock reports are monitored and managed
Output Class 3: Providing policy advice and support
Measure: An average survey score of at least 4.5 in each area.
Status: On track. This survey is completed annually at year-end and reported in the Annual Report
Measure: All fund use is in accordance with PHARMAC policy.
Status: On track. Policy is adhered to.
Last updated: 1 May 2017